文献リスト

1）Mehta A, Clarke JT, Giugliani R, et al; FOS investigators. Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey. J Med Genet. 2009; 46: 548-52

2）衛藤義勝，監修．Fabry病診断治療ハンドブック．東京: E・N MEDIX社; 2015

3）Redonnet-Vernhet I, Ploos van Amstel JK, Jansen RP, et al. X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene. J Med Genet. 1996; 33: 682-8

4）Germain DP, Echevarria L. Tissue-specific X chromosome inactivation studies as a decision-making criteria for enzyme replacement therapy in female heterozygotes for Fabry disease. Mol Genet Metab. 2014; 111: S45

5）Kolodny E, Fellgiebel A, Hilz MJ, et al. Cerebrovascular Involvement in Fabry Disease: Current Status of Knowledge. Stroke. 2015; 46: 302-13

6）Varga Z, Gelpi E, Rohonyi B, et al. Megadolichobasilar anomaly with thrombosis in a family with Fabryʼs disease and a novel mutation in the alpha-galactosidase A gene. Brain. 2005; 128: 2078-83

7）Rombach SM, Smid BE, Linthorst GE, et al. Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages. J Inherit Metab Dis. 2014; 37: 341-52

8）Politei J, Schenone AB, Burlina A, et al. Vertebrobasilar dolichoectasia in Fabry Disease: the earliest marker of neurovascular involvement? J Inborn Errors Metab Screening. 2014; 2: 232

9）Fellgiebel A, Keller I, Martus P, et al. Basilar artery diameter is a potential screening tool for Fabry disease in young stroke patients. Cerebrovasc Dis. 2011; 31: 294-9

10）Fellgiebel A, Keller I, Marin D, et al. Diagnostic utility of different MRI and MR angiography measures in Fabry disease. Neurology. 2009; 72: 63-8

11）Takanashi J, Barkovich AJ, Dillon WP, et al. T1 hyperintensity in the pulvinar: key imaging feature for diagnosis of Fabry disease. AJNR Am J Neuroradiol. 2003; 24: 916-21

12）Moore DF, Ye F, Schiffmann R, et al. Increased signal intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign of Fabry disease. AJNR Am J Neuroradiol. 2003; 24: 1096-101

13）Burlina AP, Manara R, Caillaud C, et al. The pulvinar sign: frequency and clinical correlations in Fabry disease. J Neurol. 2008; 255: 738-44

14）Uçeyler N, Homola GA, Guerrero González H, et al. Increased arterial diameters in the posterior cerebral circulation in men with Fabry disease. PLoS One. 2014; 9: e87054

15）Tanislav C, Kaps M, Rolfs A, et al. Frequency of Fabry disease in patients with small-fibre neuro-pathy of unknown aetiology: a pilot study. Eur J Neurol. 2011; 18: 631-6

16）Sestito S, Ceravolo F, Concolino D. Anderson-Fabry disease in children. Curr Pharm Des. 2013; 19: 6037-45

17）Hilz MJ, Brys M, Marthol H, et al. Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy. Neurology. 2004; 62: 1066-72

18）Sims K, Politei J, Banikazemi M, et al. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke. 2009; 40: 788-94

19）Baptista MV, Ferreira S, Pinho-E-Melo, et al; PORTuguese Young STROKE Investigators. Mutations of the GLA gene in young patients with stroke: the PORTYSTROKE study-screening genetic conditions in Portuguese young stroke patients. Stroke. 2010; 41: 431-6

20）Nakamura K, Sekijima Y, Nakamura K, et al. Cerebral hemorrhage in Fabryʼs disease. J Hum Genet. 2010; 55: 259-61

21）Chang YH, Hwang SK. A case of cerebral aneurysmal subarachnoid hemorrhage in Fabryʼs disease. J Korean Neurosurg Soc. 2013; 53: 187-9

22）Reisin RC, Romero C, Marchesoni C, et al. Brain MRI findings in patients with Fabry disease. J Neurol Sci. 2011; 305: 41-4

23）Brouns R, Thijs V, Eyskens F, et al; BeFaS Investigators. Belgian Fabry study: prevalence of Fabry disease in a cohort of 1000 young patients with cerebrovascular disease. Stroke. 2010; 41: 863-8

24）Rombach SM, Twickler TB, Aerts JM, et al. Vasculopathy in patients with Fabry disease: current controversies and research directions. Mol Genet Metab. 2010; 99: 99-108

25）Moore DF, Kaneski CR, Askari H, et al. The cerebral vasculopathy of Fabry disease. J Neurol Sci. 2007; 257: 258-63

26）Buechner S, Moretti M, Burlina AP, et al. Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study. J Neurol Neurosurg Psychiatry. 2008; 79: 1249-54

27）Go AS, Mozaffarian D, Roger VL, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation. 2013; 127: e6-245

28）Ginsberg L, Mehta A, Beck M, et al. Nervous system manifestations of Fabry disease: data from FOS - the Fabry Outcome Survey. In: Fabry Disease: Perspectives From 5 Years of FOS. Oxford: Oxford PharmaGenesis 2006

29）Grewal RP. Stroke in Fabryʼs disease. J Neurol. 1994; 241: 153-6

30）Moore DF, Scott LT, Gladwin MT, et al. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation. 2001; 104: 1506-12

31）Gupta S, Ries M, Kotsopoulos S, et al. The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women. Medicine (Baltimore). 2005; 84: 261-8

32）Vedder AC, Linthorst GE, van Breemen MJ, et al. The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis. 2007; 30: 68-78

33）Rolfs A, Böttcher T, Zschiesche M, et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet. 2005; 366: 1794-6

34）Wozniak MA, Kittner SJ, Tuhrim S, et al. Frequency of unrecognized Fabry disease among young European-American and African-American men with first ischemic stroke. Stroke. 2010; 41: 78-81

35）Rolfs A, Fazekas F, Grittner U, et al; Stroke in Young Fabry Patients (SIFAP) Investigators. Acute cerebrovascular disease in the young: the Stroke in Young Fabry Patients study. Stroke. 2013; 44: 340-9

36）Sarikaya H, Yilmaz M, Michael N, et al. Zurich Fabry study-prevalence of Fabry disease in young patients with first cryptogenic ischaemic stroke or TIA. Eur J Neurol. 2012; 19: 1421-6

37）Dubuc V, Moore DF, Gioia LC, et al. Prevalence of Fabry disease in young patients with cryptogenic ischemic stroke. J Stroke Cerebrovasc Dis. 2013; 22: 1288-92

38）Shi Q, Chen J, Pongmoragot J, et al. Prevalence of Fabry disease in stroke patients--a systematic review and meta-analysis. J Stroke Cerebrovasc. 2014; 23: 985-92

39）Lidove O, Joly D, Touzé E. Letter regarding Brouns et al, Baptista et al, and Wozniak et al. Stroke. 2011; 42: e4-5

40）Linthorst GE, Ginsberg L. Prevalence of Fabry disease in TIA/stroke cohorts. What defines Fabry disease? Eur J Neurol. 2012; 19: 1383-4

41）Takao M, Mori T, Orikasa H, et al. Postmortem diagnosis of Fabry disease with acromegaly and a unique vasculopathy. Virchows Arch. 2007; 451: 721-7

42）Warnock DG, Ortiz A, Mauer M, et al. Fabry Registry. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transplant. 2012; 27: 1042-9

43）von Sarnowski, Putaala J, Grittner U, et al. Lifestyle risk factors for ischemic stroke and transient ischemic attack in young adults in the Stroke in Young Fabry Patients study. Stroke. 2013; 44: 119-25

44）Barris-Oliveira AC, Müller KB, Turaça LT, et al. Higher frequency of paraoxonase gene polymorphism and cardiovascular impairment among Brazilian Fabry Disease patients. Clin Biochem. 2012; 45: 1459-62

45）Altarescu G, Haim S, Elstein D. Angiotensinogen promoter and angiotensinogen II receptor type 1 gene polymorphisms and incidence of ischemic stroke and neurologic phenotype in Fabry disease. Biomarkers. 2013; 18: 595-600

46）Kaneski CR, Moore DF, Ries M, et al. Myeloperoxidase predicts risk of vasculopathic events in hemizgygous males with Fabry disease. Neurology. 2006; 67: 2045-7

47）Kikumoto Y, Kai Y, Morinaga H, et al. Fabry disease exhibiting recurrent stroke and persistent inflammation. Intern Med. 2010; 49: 2247-52

48）Demuth K, Germain DP. Endothelial markers and homocysteine in patients with classic Fabry disease. Acta Paediatr Suppl. 2002; 91: 57-61

49）Fedi S, Gensini F, Gori AM, et al. Homocysteine and tissue factor pathway inhibitor levels in patients with Fabryʼs disease. J Thromb Haemost. 2005; 3: 2117-9 d

50）Niemann M, Weidemann F. A dangerous combination: Fabry disease and factor V Leiden. Intern Med J. 2012; 42: 1270-1

51）Tchan M, Sillence D. Fabry disease and Factor V Leiden: a potent vascular risk combination. Intern Med J. 2011; 41: 422-6

52）Gessoni G, Valverde S, Canistro R, et al. Factor V Leiden in Chioggia: a prevalence study in patients with venous thrombosis, their blood relatives and the general population. Blood Transfus. 2010; 8: 193-5

53）Lenders M, Karabul N, Duning T, et al. Thromboembolic events in Fabry disease and the impact of factor V Leiden. Neurology. 2015; 84: 1009-16

54）Ro A, Hara M, Takada A. The factor V Leiden mutation and the prothrombin G20210A mutation was not found in Japanese patients with pulmonary thromboembolism. Thromb Haemost. 1999; 82: 1769

55）Vedder AC, Biró E, Aerts JM, et al. Plasma markers of coagulation and endothelial activation in Fabry disease: impact of renal impairment. Nephrol Dial Transplant. 2009; 24: 3074-81

56）Igarashi T, Sakuraba H, Suzuki Y. Activation of platelet function in Fabryʼs disease. Am J Hematol. 1986; 22: 63-7

57）Tosoni A, Nebuloni M, Zerbi P, et al. Ultrastructural study of renal involvement in two females with Anderson-Fabry disease. Ultrastruct Pathol. 2005; 29: 203-7

58）Shen JS, Meng XL, Moore DF, et al. Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol Genet Metab. 2008; 95: 163-8

59）DeGraba T, Azhar S, Dignat-George F, et al. Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol. 2000; 47: 229-33

60）Shu L, Shayman JA. Caveolin-associated accumulation of globotriaosylceramide in the vascular endothelium of alpha-galactosidase A null mice. J Biol Chem. 2007; 282: 20960-7

61）Park S, Kim JA, Joo KY, et al. Globotriaosylceramide leads to K(Ca)3.1 channel dysfunction: a new insight into endothelial dysfunction in Fabry disease. Cardiovasc Res. 2011; 89: 290-9

62）Barbey F, Brakch N, Linhart A, et al. Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition. Arterioscler Thromb Vasc Biol. 2006; 26: 839-44

63）Brakch N, Dormond O, Bekri S, et al. Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease. Eur Heart J. 2010; 31: 67-76

64）Barbey F, Qanadli SD, Juli C, et al. Aortic remodelling in Fabry disease. Eur Heart J. 2010; 31: 347-53

65）Rombach SM, van den Bogaard B, de Groot E, et al. Vascular aspects of Fabry disease in relation to clinical manifestations and elevations in plasma globotriaosylsphingosine. Hypertension. 2012; 60: 998-1005

66）Kalliokoski RJ, Kalliokoski KK, Penttinen M, et al. Structural and functional changes in peripheral vasculature of Fabry patients. J Inherit Metab Dis. 2006; 29: 660-6

67）Sho E, Sho M, Singh TM, et al. Arterial enlargement in response to high flow requires early expression of matrix metalloproteinases to degrade extracellular matrix. Exp Mol Pathol. 2002; 73: 142-53

68）Tronc F, Mallat Z, Lehoux S, et al. Role of matrix metalloproteinases in blood flow-induced arterial enlargement: interaction with NO. Arterioscler Thromb Vasc Biol. 2000; 20: E120-6

69）Fischer J, Whitney D. Attention gates visual coding in the human pulvinar. Nat Commun. 2012; 3: 1051

70）Tomizawa Y, Okuzumi A, Shiotsuki H, et al. A Patient with the GLA p. E66Q Mutation Exhibiting Vascular Parkinsonism and Bilateral Pulvinar Lesions. Intern Med. 2015; 54: 2503-6

71）Burlina AP, Politei J, Cinque S, et al. The pulvinar sign in Fabry patients: the first report in female patients. J Neurol. 2012; 259: 1227-8

72）Fazekas F, Enzinger C, Schmidt R, et al. Brain magnetic resonance imaging findings fail to suspect fabry disease in young patients with an acute cerebrovascular event. Stroke. 2015; 46: 1548-53

73）Kaye EM, Kolodny EH, Logigian EL, et al. Nervous system involvement in Fabryʼs disease: clinicopathological and biochemical correlation. Ann Neurol. 1988; 23: 505-9

74）deVeber GA, Schwarting GA, Kolodny EH, et al. Fabry disease: immunocytochemical characterization of neuronal involvement. Ann Neurol. 1992; 31: 409-15

75）Crutchfield KE, Patronas NJ, Dambrosia JM, et al. Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology. 1998; 50: 1746-9

76）Fellgiebel A, Müller MJ, Mazanek M, et al. White matter lesion severity in male and female patients with Fabry disease. Neurology. 2005; 65: 600-2

77）Steinicke R, Gaertner B, Grittner U, et al. Kidney function and white matter disease in young stroke patients: analysis of the stroke in young Fabry patients study population. Stroke. 2012; 43: 2382-8

78）Matute C, Domercq M, Pérez-Samartín A, et al. Protecting white matter from stroke injury. Stroke. 2013; 44: 1204-11

79）Rost N, Metterville DR, Cloonan LK, et al. White matter hyperintensity volume assessment in patients with Fabry disease [abstract 198]. Mol Genet Metab. 2013; 108 Suppl: S80

80）Hilz MJ, Kolodny EH, Brys M, et al. Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease. J Neurol. 2004; 251: 564-70

81）Uçeyler N, He L, Kahn AK, et al. Cerebral blood flow in patients with Fabry disease as measured by Doppler sonography is not different from that in healthy individuals and is unaffected by treatment. J Ultrasound Med. 2012; 31: 463-8

82）Moore DF, Altarescu G, Ling GS, et al. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke. 2002; 33: 525-31

83）Moore DF, Herscovitch P, Schiffmann R. Selective arterial distribution of cerebral hyperperfusion in Fabry disease. J Neuroimaging. 2001; 11: 303-7

84）Itoh Y, Esaki T, Cook M, et al. Local and global cerebral blood flow and glucose utilization in the alpha-galactosidase A knockout mouse model of Fabry disease. J Neurochem. 2001; 79: 1217-24

85）Azevedo E, Mendes A, Seixas D, et al. Functional transcranial Doppler: presymptomatic changes in Fabry disease. Eur Neurol. 2012; 67: 331-7

86）Fellgiebel A, Gartenschläger M, Wildberger K, et al. Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease. Cerebrovasc Dis. 2014; 38: 448-56

87）Germain DP, Charrow J, Desnick RJ, et al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet. 2015; 52: 353-8

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp